ŞENNUR GÖRGÜLÜ

Dr. ŞENNUR GÖRGÜLÜ

Dr.
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

17 June 2020 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
GYGülsel Yurtdaş-Kırımlıoğlu
Gülsel Yurtdaş-Kırımlıoğlu
ŞGŞENNUR GÖRGÜLÜ
ŞENNUR GÖRGÜLÜ
MBMurat Sami Berkman
Murat Sami Berkman
Objective: The purpose of this study was the design ibuprofen (IBU) loaded unique Eudragit® RS 100 (ERS) and/or octadecylamine modified PLGA nanoparticles (NPs) for cancer treatment. Significance: The rational for this approach is to bring a new approach to cancer treatment with modification of IBU loaded PLGA NPs with ERS and/or octadecylamine by means of smaller particle size (PS), cationic surface, biocompatible nature and investigating their selective efficacy on lung cell lines (A549 lung cancer cell and CCD-19Lu normal cell line). Methods: IBU encapsulated PLGA based NPs were prepared and characterized for physical and solid-state analyses. In vitro release, MTT and determination of apoptotic pathways were performed. Results: Considering characterizations; B, C, E, F, H and K formulations with higher EE%, smaller PS and encouraging higher ZP were chosen for further experiments were intended to enhance anticancer action and apoptotic behavior. Formulations were showed biphasic release profile with extended release manner (Korsmeyer-Peppas model with a diffusion-controlled mechanism). The NPs effect on lung cancer cells with high specificity and affinity was demonstrated by MTT study. It was found that the effect of IBU was increased 4-28 times over the pure form. Annexin V-FITC/PI staining method, FITC Active Caspase-3 staining method and mitochondrial membrane potential detection analyses was performed to determine the apoptotic pathways by flow cytometry. Conclusion: E coded NP is selected as a promising candidate with its highly specific affinity for human lung adenocarcinoma cells and could induce cell death effectively and be a potent system to treat lung cancer.

28 October 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Belgin SeverBelgin Sever
Belgin Sever
HSHasan Soybir
Hasan Soybir
ŞGŞENNUR GÖRGÜLÜ
ŞENNUR GÖRGÜLÜ
ZCZerrin Canturk
Zerrin Canturk
Mehlika Dilek AltıntopMehlika Dilek Altıntop
Mehlika Dilek Altıntop
Dipeptidyl peptidase-4 (DPP-4) inhibition has been recognized as a promising approach to develop safe and potent antidiabetic agents for the management of type 2 diabetes. In this context, new thiosemicarbazones (2a–o) were prepared efficiently by the reaction of aromatic aldehydes with 4-[4-(1H-pyrazol-1-yl)phenyl]thiosemicarbazide (1), which was obtained via the reaction of 4-(1H-pyrazol-1-yl)phenyl isothiocyanate with hydrazine hydrate. Compounds 2a–o were evaluated for their DPP-4 inhibitory effects based on a convenient fluorescence-based assay. 4-[4-(1H-pyrazol-1-yl)phenyl]-1-(4-bromobenzylidene)thiosemicarbazide (2f) was identified as the most effective DPP-4 inhibitor in this series with an IC50 value of 1.266 ± 0.264 nM when compared with sitagliptin (IC50 = 4.380 ± 0.319 nM). MTT test was carried out to assess the cytotoxic effects of compounds 2a–o on NIH/3T3 mouse embryonic fibroblast (normal) cell line. According to cytotoxicity assay, compound 2f showed cytotoxicity towards NIH/3T3 cell line with an IC50 value higher than 500 µM pointing out its favourable safety profile. Molecular docking studies indicated that compound 2f presented π-π interactions with Arg358 and Tyr666 via pyrazole scaffold and 4-bromophenyl substituent, respectively. Overall, in vitro and in silico studies put emphasis on that compound 2f attracts a great notice as a drug-like DPP-4 inhibitor for further antidiabetic research.

28 December 2020 in Combinatorial Chemistry & High Throughput Screening
Verified
Journal Article
Closed access
PDF file
A. Alper ÖztürkA. Alper Öztürk
A. Alper Öztürk
İNİrem Namlı
İrem Namlı
KGKadri Güleç
Kadri Güleç
ŞGŞENNUR GÖRGÜLÜ
ŞENNUR GÖRGÜLÜ
Aims: To prepare lamivudine (LAM)-loaded-nanoparticles (NPs) that can be used in lung cancer treatment. To change the antiviral indication of LAM to anticancer.Background: The development of anticancer drugs is a difficult process. One approach to accelerate the availability of drugs is to reclassify drugs approved for other conditions as anticancer. The most common route of administration of anticancer drugs is intravenous injection. Oral administration of anticancer drugs may considerably change current treatment modalities of chemotherapy and improve the life quality of cancer patients. There is also a potentially significant economic advantage.Objective: To characterize the LAM-loaded-NPs and examine the anticancer activity.Methods: LAM-loaded-NPs were prepared using Nano Spray-Dryer. Properties of NPs were elucidated by particle size (PS), polydispersity index (PDI), zeta potential (ZP), SEM, encapsulation efficiency (EE%), dissolution, release kinetics, DSC and FT-IR. Then, the anticancer activity of all NPs was examined.Results: The PS values of the LAM-loaded-NPs were between 373 and 486 nm. All NPs prepared have spherical structure and positive ZP. EE% was in a range of 61-79%. NPs showed prolonged release and the release kinetics fitted to the Weibull model. NPs structures were clarified by DSC and FT-IR analysis. The results showed that the properties of NPs were directly related to the drug:polymer ratio of feed solution. NPs have potential anticancer properties against A549 cell line at low concentrations and non-toxic to CCD 19-Lu cell line.Conclusion: NPs have potential anticancer properties against human lung adenocarcinoma cells and may induce cell death effectively and be a potent modality to treat this type of cancer. These experiments also indicate that our formulations are non-toxic to normal cells. It is clear that this study would bring a new perspective to cancer therapy.

7 June 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
BKBeril Kurban
Beril Kurban
TTTuğba Tuncel
Tuğba Tuncel
ŞGŞENNUR GÖRGÜLÜ
ŞENNUR GÖRGÜLÜ
FATİH KARFATİH KAR
FATİH KAR
AÖAlper Öztürk
Alper Öztürk
TÖTemel Özek
Temel Özek
Lung cancer is one of the most common causes of death in the world. Considering the severe side effects, toxicity and high costs of chemotherapeutics used in cancer treatment, there is a need for more economical and natural treatment methods such as essential oils. The purpose of this study is to determine the efficacy of Canarium commune (Elemi) essential oil (EO) and nanoparticles. Elemi EO is analysed by GC‐FID/MS. The antiproliferative effect of Elemi EO and prepared nanoparticles on human lung adenocarcinoma (A549) and their effect on normal fibroblast cells (CCD‐19Lu) were determined by the MTT test. The levels of TAS, TOS, CYCS, CASP3, TNF‐α and IL‐6 parameters of the experimental groups were determined using specific ELISA. BAX and Bcl‐2 genes were studied with qRT‐PCR to investigate the different ways that cancer cells undergo apoptosis. Limonene (53.7%), a‐phellandrene (14.5%) and elemol (10.1%) were the major components of Elemi EO. 24‐Hour IC50 values in the cells were measured for Elemi EO; A549: 1199 μg/mL, CCD‐19Lu: 37.181 μg/mL. TAS and TOS values were found to be higher in cancer cells than in normal cells, and it was found that cancerous cells were dragged into stress and that cancer cells were directed to apoptosis. BAX genes stimulation supported the results. It was determined that Elemi EO and nanoparticles showed anticancer activity without damaging normal cells. Based on these promising results, potential drug candidate Elemi EO loaded nanoparticles may be cell‐specific targeted, oral use possible, new generation nanoparticular drugs.

2 June 2024 in Drug Development Research
Verified
Journal Article
Open access
UÇUlviye ACAR ÇEVİK
Ulviye ACAR ÇEVİK
ICIsmail Celik
Ismail Celik
ŞGŞENNUR GÖRGÜLÜ
ŞENNUR GÖRGÜLÜ
ZIZeynep Deniz Şahin Inan
Zeynep Deniz Şahin Inan
HBHayrani Eren Bostancı
Hayrani Eren Bostancı
ZKZafer Asım Kaplancıklı
Zafer Asım Kaplancıklı
We report herein, the design and synthesis of benzimidazole‐oxadiazole derivatives as new inhibitors for vascular endothelial growth factor receptor‐2 (VEGFR‐2). The designed members were assessed for their in vitro anticancer activity against three cancer cell lines and two normal cell lines; A549, MCF‐7, PANC‐1, hTERT‐HPNE and CCD‐19Lu. Compounds 4c and 4d were found to be the most effective compounds against three cancer cell lines. Compounds 4c and 4d were then tested for their in vitro VEGFR‐2 inhibitory activity, safety profiles, and selectivity indices using the normal hTERT‐HPNE and CCD‐19Lu cell lines. It was determined that compound 4c was the most effective and safe member of the produced chemical family. Vascular endothelial growth factor A (VEGFA) immunolocalizations of compounds 4c and 4d were evaluated relative to control by VEGFA immunofluorescence staining. Compounds 4c and 4d inhibited VEGFR‐2 enzyme with half‐maximal inhibitory concentration values of 0.475 ± 0.021 and 0.618 ± 0.028 µM, respectively. Molecular docking of the target compounds was carried out in the active site of VEGFR‐2 (Protein Data Bank: 4ASD).